← All trials
NCT06682975
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Nov 11, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 92
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zealand PharmaLead sponsor
- Zealand PharmaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.